News | Contrast Media | September 07, 2017

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents

Administration looks to solicit opinions and recommendations on regulatory approaches to administration of GBCAs

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell

September 7, 2017 — The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory Committee (MIDAC) on Sept. 8 to discuss regulatory approaches for use of gadolinium-based contrast agents (GBCAs).

In a statement, the administration said, “FDA has convened this advisory committee to seek opinions and recommendations on regulatory approaches to the issue of gadolinium retention in the brain and other body organs following administration of gadolinium based contrast agents (GBCAs). The evidence indicating retention following the use of GBCAs has led to concerns that gadolinium retention may cause adverse reactions, if not immediately then at some later date. FDA will ask the committee to focus on scientific facts; observational data; nonclinical, clinical and epidemiological study findings; post-marketing adverse event reports; and regulatory requirements in considering its responses to FDA questions.”

The statement continued, “FDA’s approach has been educational: alerting the public and clinicians to the retention phenomenon but not issuing any restrictions on use because toxic effects in humans have not been established.

We now seek advice from the committee on the strength of the scientific evidence that would support potential regulatory actions such as labeling changes in relation to gadolinium retention. We also seek suggestions on the design of further epidemiologic and other studies to investigate potential adverse events associated with gadolinium retention in humans...”

The statement concluded, “…It is important to note that FDA’s intention in convening the current Advisory Committee is to solicit advice limited in scope to safety issues surrounding post-GBCA gadolinium retention in patients with normal renal function.”

The FDA’s decision to convene the MIDAC on this topic follows the May 22, 2017 update to its previous Drug Safety Communication entitled “FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.”

For more information: www.fda.gov

 

Related Content on MRI Gadolinium Retention in the Brain

FDA: No Harm in MRI Gadolinium Retention in the Brain

Recent Trends and Developments in Contrast Media

VIDEO: MRI Gadolinium Contrast Retention in the Brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

 

Related Content

European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Technical University of Munich, Munich Compact Light Source, MuCLS, angiography, contrast agents

(a) Photograph of the sample in waterbath. (b) Empty image of full MuCLS beam. (c) Quasi-mono-energetic angiography image of a porcine heart acquired at the MuCLS, with iodine-based contrast agent injected into the left coronary artery. Visible are the left anterior descending artery (LAD) and the left circumflex artery (LCX). Image courtesy of the authors.

News | Angiography| March 10, 2017
The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients,...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Overlay Init